These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 16767297

  • 1. [Microalbuminuria: cardiovascular and renal risk factors underestimated in clinical practice].
    Zanella MT.
    Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):313-21. PubMed ID: 16767297
    [Abstract] [Full Text] [Related]

  • 2. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D.
    Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
    [Abstract] [Full Text] [Related]

  • 3. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
    Jacobsen P, Rossing K, Parving HH.
    Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
    [Abstract] [Full Text] [Related]

  • 4. Treatment of microalbuminuria in patients with type 2 diabetes mellitus.
    Jerums G, MacIsaac RJ.
    Treat Endocrinol; 2002 May; 1(3):163-73. PubMed ID: 15799209
    [Abstract] [Full Text] [Related]

  • 5. Microalbuminuria: a common, independent cardiovascular risk factor, especially but not exclusively in type 2 diabetes.
    Donnelly R, Yeung JM, Manning G.
    J Hypertens Suppl; 2003 Mar; 21(1):S7-12. PubMed ID: 12769161
    [Abstract] [Full Text] [Related]

  • 6. The RAAS in the pathogenesis and treatment of diabetic nephropathy.
    Ruggenenti P, Cravedi P, Remuzzi G.
    Nat Rev Nephrol; 2010 Jun; 6(6):319-30. PubMed ID: 20440277
    [Abstract] [Full Text] [Related]

  • 7. Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study.
    Morikawa A, Ishizeki K, Iwashima Y, Yokoyama H, Muto E, Oshima E, Sekiguchi M, Miura T, Itoh H, Haneda M.
    Clin Exp Nephrol; 2011 Dec; 15(6):848-53. PubMed ID: 21823043
    [Abstract] [Full Text] [Related]

  • 8. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 9. Slowing progression along the renal disease continuum.
    Kopyt NP.
    J Am Osteopath Assoc; 2005 Apr; 105(4):207-15. PubMed ID: 15928338
    [Abstract] [Full Text] [Related]

  • 10. Monitoring and managing urinary albumin excretion: practical advice for primary care clinicians.
    Bakris GL, Kuritzky L.
    Postgrad Med; 2009 Jul; 121(4):51-60. PubMed ID: 19641270
    [Abstract] [Full Text] [Related]

  • 11. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA.
    Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
    [Abstract] [Full Text] [Related]

  • 12. [Risk and prevention of diabetic nephropathy].
    Ravera M, Re M, Deferrari G.
    G Ital Nefrol; 2007 May; 24 Suppl 38():13-9. PubMed ID: 17922442
    [Abstract] [Full Text] [Related]

  • 13. Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus.
    Agha A, Bashir K, Anwar E.
    Nepal Med Coll J; 2007 Jun; 9(2):79-83. PubMed ID: 17899953
    [Abstract] [Full Text] [Related]

  • 14. Recommendations for the management of special populations: renal disease in diabetes.
    Raij L.
    Am J Hypertens; 2003 Nov; 16(11 Pt 2):46S-49S. PubMed ID: 14625161
    [Abstract] [Full Text] [Related]

  • 15. Different patterns of one-year evolution of microalbuminuria in hypertensive patients treated with different inhibitors of the renin-angiotensin system.
    Cotter J, Oliveira P, Cunha P, Polónia J.
    Rev Port Cardiol; 2008 Nov; 27(11):1395-404. PubMed ID: 19227807
    [Abstract] [Full Text] [Related]

  • 16. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes.
    Mogensen CE.
    J Intern Med; 2003 Jul; 254(1):45-66. PubMed ID: 12823642
    [Abstract] [Full Text] [Related]

  • 17. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB, Britton ML.
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [Abstract] [Full Text] [Related]

  • 18. Microalbuminuria, insulin resistance, diabetes, hypertension, and kidney function: the latest concepts in pathology and pharmacologic treatment.
    Barri YM, Palmer BF, Ram CV.
    Postgrad Med; 2005 Dec; 118(6 Suppl Beta-Blockers):34-45. PubMed ID: 19667709
    [Abstract] [Full Text] [Related]

  • 19. Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial.
    Maione A, Nicolucci A, Craig JC, Tognoni G, Moschetta A, Palasciano G, Pugliese G, Procaccini DA, Gesualdo L, Pellegrini F, Strippoli GF, LIRICO study group.
    J Nephrol; 2007 Dec; 20(6):646-55. PubMed ID: 18046666
    [Abstract] [Full Text] [Related]

  • 20. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
    Burnier M, Zanchi A.
    J Hypertens; 2006 Jan; 24(1):11-25. PubMed ID: 16331093
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.